Timeline
Through innovative research and product development, InnoTherapy has established a distinguished portfolio of medical sealants while steadily expanding its position in the global market.
InnoTherapy continues to expand the scope of research and development of bio-therapeutics through strategic R&D collaboration programs that will drive further technological innovation.
Timeline
November 7
2020
Investment and strategic alliance with Finemedix
InnoSEAL approved in Israel, Argentina, and Malaysia
November 7
2019
InnoTherapy listed on KOSDAQ stock exchange
InnoSEAL Plus (absorbable hemostat) approval in Korea
EndoSil (absorbable hemostat) approval in Korea
InnoSEAL approved in Hong Kong, Pakistan
Investment from NVC
November 7
2018
InnoSEAL brand registration in Japan
InnoSEAL Plus pivotal clinical study completed
EndoSil pivotal clinical study completed
ISO 13485 certification
November 7
2017
InnoSEAL Plus first in human clinical trial completed
InnoSEAL Plus pivotal clinical study plan approved
EndoSil pivotal clinical study plan completed
Seoul manufacturing plant GMP certification
November 7
2016
InnoSEAL FDA 510(k) cleared
InnoSEAL Plus first-in-human clinical study plan approved
November 7
2015
InnoSEAL approval in Korea
Establishment of InnoTherapy America, Inc. in the U.S. (New Jersey)
GMP certification
Relocation of corporate office & Establishment of the Seoul Manufacturing Plant (Factory 2)
November 7
2014
NET certification for New Health Technology (Korean Ministry of Health and Welfare)
November 7
2013
Establishment of Daejeon branch
Establishment of Research Center & Completion of Cleanroom Facility
November 7
2010
Foundation of InnoTherapy Inc.